Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus DEXILANT SOLUTAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus DEXILANT SOLUTAB.
ASPIRIN; OMEPRAZOLE vs DEXILANT SOLUTAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aspirin irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis and platelet aggregation. Omeprazole is a proton pump inhibitor that irreversibly binds to H+/K+-ATPase in gastric parietal cells, reducing gastric acid secretion.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Aspirin 81 mg orally once daily plus omeprazole 20 mg orally once daily.
30 mg orally once daily for 4-8 weeks; for non-erosive GERD, 30 mg orally once daily for 4 weeks; for erosive esophagitis, 60 mg orally once daily for up to 8 weeks; for maintenance of healed EE and relief of heartburn, 30 mg orally once daily. Administer without regard to food; dissolve tablet in water.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate half-life 2-3 hours at low doses, increasing to >20 hours at high doses due to saturable hepatic metabolism; clinically, dosing interval adjusted for antiplatelet effect (low dose) vs anti-inflammatory (high dose). Omeprazole: 0.5-1 hour; no accumulation on repeated dosing; metabolized via CYP2C19 and CYP3A4.
Terminal elimination half-life is approximately 1-2 hours; however, the pharmacodynamic half-life (duration of acid suppression) is prolonged due to accumulation in parietal cell canaliculi.
Aspirin: renal elimination of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid); ~10% excreted unchanged in urine; dose-dependent due to saturable metabolism. Omeprazole: ~80% eliminated as metabolites in urine, ~20% in feces via biliary excretion.
Renal (approx. 53% as metabolites, <2% as unchanged drug), biliary/fecal (approx. 47%).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor